Minerva Surgical (UTRS – Research Report) received a Sell rating and price target from J.P. Morgan analyst Robbie Marcus yesterday. The company’s shares closed yesterday at $1.74.
According to TipRanks, Marcus is a 4-star analyst with an average return of 6.9% and a 45.70% success rate. Marcus covers the Healthcare sector, focusing on stocks such as Minerva Surgical, Baxter International, and Intuitive Surgical.
The word on The Street in general, suggests a Hold analyst consensus rating for Minerva Surgical with a $5.00 average price target.
See today’s best-performing stocks on TipRanks >>
Based on Minerva Surgical’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $12.97 million and a GAAP net loss of $5.61 million. In comparison, last year the company earned a revenue of $14.11 million and had a GAAP net loss of $14.1 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Minerva Surgical Inc is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women.
Read More on UTRS:
- Challenger Limited (CFIGF) was upgraded to a Hold Rating at J.P. Morgan
- Appen Ltd. (APPEF) was downgraded to a Sell Rating at J.P. Morgan
- Bendigo & Adelaide Bank Ltd. (BXRBF) was downgraded to a Sell Rating at J.P. Morgan
- AUTO1 Group SE (ATOGF) was upgraded to a Buy Rating at J.P. Morgan
- Health Catalyst (HCAT) was downgraded to a Hold Rating at J.P. Morgan
